Selected article for: "clinical outcome and retrospective study"
Author: Bein, Thomas; Grasso, Salvatore; Moerer, Onnen; Quintel, Michael; Guerin, Claude; Deja, Maria; Brondani, Anita; Mehta, Sangeeta
Title: The standard of care of patients with ARDS: ventilatory settings and rescue therapies for refractory hypoxemia
  • Document date: 2016_4_4
    • ID: krpg9u1u_45
    Snippet: Despite significant improvements in oxygenation, inhaled nitric oxide (iNO) does not reduce mortality in patients with ARDS regardless of the severity of hypoxemia, and it may increase the risk of renal impairment [80] . A recent meta-analysis which included nine randomized trials (n = 1142 patients) with no between-trial heterogeneity (I = 0 %) showed that iNO did not reduce mortality in patients with severe ARDS (risk ratio 1.01; 95 % CI 0.78-1.....
    Document: Despite significant improvements in oxygenation, inhaled nitric oxide (iNO) does not reduce mortality in patients with ARDS regardless of the severity of hypoxemia, and it may increase the risk of renal impairment [80] . A recent meta-analysis which included nine randomized trials (n = 1142 patients) with no between-trial heterogeneity (I = 0 %) showed that iNO did not reduce mortality in patients with severe ARDS (risk ratio 1.01; 95 % CI 0.78-1.32) nor in mild-moderate ARDS (risk ratio 1.12; 95 % CI 0.89-1.42) [81] . Moreover, analysis of PaO 2 /FiO 2 ratio subgroups ranging from 70 to 200 mmHg did not identify a threshold for which iNO reduces mortality [80] . The effectiveness, safety, and cost of inhaled epoprostenol (iEPO) versus iNO was addressed by a retrospective single-center study of 105 patients [82] , but there were no between-group differences in several clinical and outcome parameters.

    Search related documents:
    Co phrase search for related documents
    • ARDS patient and oxygenation significant improvement: 1, 2
    • ARDS patient and randomized trial: 1, 2, 3
    • ARDS patient and risk ratio: 1, 2
    • ARDS patient and severe ARDS patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ARDS patient and severe ARDS patient mortality: 1
    • ARDS patient mortality and severe ARDS patient: 1
    • ARDS patient mortality and severe ARDS patient mortality: 1
    • cost safety and group difference: 1, 2
    • cost safety and randomized trial: 1, 2, 3, 4, 5, 6
    • cost safety and risk ratio: 1, 2, 3
    • cost safety effectiveness and randomized trial: 1, 2
    • group difference and hypoxemia severity: 1
    • group difference and randomized trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • group difference and renal impairment: 1
    • group difference and risk ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • outcome clinical parameter and randomized trial: 1
    • oxygenation significant improvement and randomized trial: 1
    • randomized trial and renal impairment: 1, 2, 3, 4, 5
    • randomized trial and risk ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25